139 related articles for article (PubMed ID: 26074454)
1. Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery.
Bianchi A; Arosio D; Perego P; De Cesare M; Carenini N; Zaffaroni N; De Matteo M; Manzoni L
Org Biomol Chem; 2015 Jul; 13(27):7530-41. PubMed ID: 26074454
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.
Pilkington-Miksa M; Arosio D; Battistini L; Belvisi L; De Matteo M; Vasile F; Burreddu P; Carta P; Rassu G; Perego P; Carenini N; Zunino F; De Cesare M; Castiglioni V; Scanziani E; Scolastico C; Casiraghi G; Zanardi F; Manzoni L
Bioconjug Chem; 2012 Aug; 23(8):1610-22. PubMed ID: 22770429
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
4. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting α(v)β(3)/α(v)β(5) integrins and IAP proteins.
Mingozzi M; Manzoni L; Arosio D; Dal Corso A; Manzotti M; Innamorati F; Pignataro L; Lecis D; Delia D; Seneci P; Gennari C
Org Biomol Chem; 2014 May; 12(20):3288-302. PubMed ID: 24737345
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.
Chen X; Plasencia C; Hou Y; Neamati N
J Med Chem; 2005 Feb; 48(4):1098-106. PubMed ID: 15715477
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes.
Dijkgraaf I; Rijnders AY; Soede A; Dechesne AC; van Esse GW; Brouwer AJ; Corstens FH; Boerman OC; Rijkers DT; Liskamp RM
Org Biomol Chem; 2007 Mar; 5(6):935-44. PubMed ID: 17340009
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3.
Colombo R; Mingozzi M; Belvisi L; Arosio D; Piarulli U; Carenini N; Perego P; Zaffaroni N; De Cesare M; Castiglioni V; Scanziani E; Gennari C
J Med Chem; 2012 Dec; 55(23):10460-74. PubMed ID: 23140358
[TBL] [Abstract][Full Text] [Related]
9. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
10. Integrin-targeted nano-sized polymeric systems for paclitaxel conjugation: a comparative study.
Eldar-Boock A; Blau R; Ryppa C; Baabur-Cohen H; Many A; Vicent MJ; Kratz F; Sanchis J; Satchi-Fainaro R
J Drug Target; 2017; 25(9-10):829-844. PubMed ID: 28737432
[TBL] [Abstract][Full Text] [Related]
11. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors.
Jin ZH; Josserand V; Foillard S; Boturyn D; Dumy P; Favrot MC; Coll JL
Mol Cancer; 2007 Jun; 6():41. PubMed ID: 17565663
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
13. Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.
Alam MR; Ming X; Fisher M; Lackey JG; Rajeev KG; Manoharan M; Juliano RL
Bioconjug Chem; 2011 Aug; 22(8):1673-81. PubMed ID: 21755983
[TBL] [Abstract][Full Text] [Related]
14. "Polymultivalent" Polymer-Peptide Cluster Conjugates for an Enhanced Targeting of Cells Expressing α
Duret D; Grassin A; Henry M; Jacquet T; Thoreau F; Denis-Quanquin S; Coll JL; Boturyn D; Favier A; Charreyre MT
Bioconjug Chem; 2017 Sep; 28(9):2241-2245. PubMed ID: 28767233
[TBL] [Abstract][Full Text] [Related]
15. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications.
Chun C; Lee SM; Kim SY; Yang HK; Song SC
Biomaterials; 2009 Apr; 30(12):2349-60. PubMed ID: 19178941
[TBL] [Abstract][Full Text] [Related]
16. Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin α
Raposo Moreira Dias A; Pina A; Dal Corso A; Arosio D; Belvisi L; Pignataro L; Caruso M; Gennari C
Chemistry; 2017 Oct; 23(58):14410-14415. PubMed ID: 28816404
[TBL] [Abstract][Full Text] [Related]
17. Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.
Redko B; Tuchinsky H; Segal T; Tobi D; Luboshits G; Ashur-Fabian O; Pinhasov A; Gerlitz G; Gellerman G
Oncotarget; 2017 Jan; 8(1):757-768. PubMed ID: 27768593
[TBL] [Abstract][Full Text] [Related]
18. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
19. Cyclic RGD-conjugated Pluronic
Lim C; Moon J; Sim T; Hoang NH; Won WR; Lee ES; Youn YS; Choi HG; Oh K; Oh KT
Int J Nanomedicine; 2018; 13():4627-4639. PubMed ID: 30127610
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent.
Huang YQ; Yuan JD; Ding HF; Song YS; Qian G; Wang JL; Ji M; Zhang Y
Eur J Med Chem; 2018 Oct; 158():82-90. PubMed ID: 30199708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
